The New England Journal of Medicine, the world's most influential and widely read medical periodical, features a study this week about a Phase 2 clinical trial of VX-770, an oral drug in development that targets the root cause of cystic fibrosis.
Site Search
Showing 1 - 10 of 245 results
News
|
May 6, 2011
|
1 min read
News
|
Nov. 8, 2011
|
2 min read
News
|
Sept. 14, 2011
|
2 min read
News
|
Sept. 22, 2009
|
3 min read
News
|
March 25, 2009
|
2 min read
News
|
March 2, 2009
|
1 min read
News
|
Nov. 17, 2010
|
3 min read
This year, Cystic Fibrosis Advocates inspired new champions in Washington, D.C. and in state capitols across the country to take action on critical CF-related issues.
News
|
Dec. 10, 2010
|
2 min read
News
|
Nov. 20, 2008
|
1 min read
News
|
May 21, 2008
|
2 min read